Bristol-Myers Squibb Analyst Ratings
Jefferies Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Cuts Target Price to $51
Hold Rating on Bristol-Myers Squibb Amid Patent Expirations and Speculative Prospects of Milvexian
Stifel Maintains Altria(MO.US) With Buy Rating
Evercore ISI Raises Price Target on AbbVie to $192 From $180, Keeps Outperform Rating
AbbVie Analyst Ratings
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $209
Piper Sandler Sticks to Its Buy Rating for AbbVie (ABBV)
Stifel Maintains Altria(MO.US) With Buy Rating, Maintains Target Price $54
United Parcel Service Analyst Ratings
Bristol-Myers Squibb Analyst Ratings
TD Cowen Initiates United Parcel Service(UPS.US) With Hold Rating, Announces Target Price $144
Barclays Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Announces Target Price $42
Barclays Reaffirms Their Sell Rating on Bristol-Myers Squibb (BMY)
Jefferies Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
Barclays Adjusts Bristol-Myers Squibb Price Target to $42 From $41, Maintains Underweight Rating
BNP Paribas Maintains IBM Corp(IBM.US) With Sell Rating, Raises Target Price to $170
Exxon Mobil Analyst Ratings
Daiwa Maintains Citigroup(C.US) With Buy Rating, Raises Target Price to $78
Daiwa Securities Adjusts Price Target on Citigroup to $78 From $81, Maintains Buy Rating